What is claimed is:

1. A compound of Formula (I), or a salt, solvate or hydrate thereof



(I)

wherein

each of R^1 and R^2 is independently selected from the group consisting of OH, OR^7, and H, provided that at least one of R^1 and R^2 is -OH or -OR^7;

R^7 is selected from the group consisting of optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, aryl C_{1-6} alkyl and acyl;

R^3 is selected from the group consisting of optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted C_{4-6} cycloalkenyl, halo, cyano, -$C(O)OR^8$, -NR^9R^{10}, -$S(O)_2NR^9R^{10}$,
-$C(O)R^{11}$, -OR^{12}, -$S(O)_n R^{13}$, and optionally substituted heterocyclyl;

R^8 is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl;

each of R^9 and R^{10} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, or alternatively, R^9 and R^{10} together with the nitrogen atom to which they are attached form a 5-7 membered cyclic saturated or unsaturated ring;

R^{11} is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, -NR^9R^{10}, and -OR^{12};

each of R^{12} and R^{13} is independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl;

R^6 is selected from the group consisting of H, halo, hydroxyl, alkoxy, optionally substituted C_{1-6} alkyl, halogenated alkyl; optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, and optionally substituted aryl C_{1-6} alkyl;

n is an integer having a value of 0, 1 or 2;

s is an integer having a value of 0, 1 or 2;

t is an integer having a value of 0 to 6;

R^5 is selected from the group consisting of H, halo, optionally substituted C_{1-6} alkyl, $-C(O)OR^{14}$, $-C(O)NR^{15}R^{16}$, aryl and $-C_{1-6}$ alkylaryl;

R^{14} is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl;

each of R^{15} and R^{16} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl; alternatively R^{15} and R^{16} together with the nitrogen to which they are attached, form a 5-7 membered cyclic saturated or unsaturated ring;

R^4 is selected from the group consisting of H, halo, cyano, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, $-(CR^{18}R^{19})_tCOOR^8$, $-(CR^{18}R^{19})_tOC(O)R^8$, $-(CR^{18}R^{19})_tNR^9R^{10}$, $-(CR^{18}R^{19})_tC(O)NR^9R^{10}$, $-(CR^{18}R^{19})_tNR^9C(O)R^8$, $-(CR^{18}R^{19})_tS(O)_2NR^9R^{10}$, $-(CR^{18}R^{19})_tCOR^{11}$, $-(CR^{18}R^{19})_tCH(O)$, $-(CR^{18}R^{19})_tOR^{12}$, $-(CR^{18}R^{19})_tS(O)_sR^{13}$, optionally substituted heterocyclic, and optionally substituted heterocyclic C_{1-6} alkyl; and

each of R^{18} and R^{19} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl.

2. The compound according to claim 1 wherein R^1 and R^2 are each OH.

3. The compound according to claim 1 wherein one of R^1 and R^2 is OH and the other is H.

4. The compound according to claim 1 wherein one of R^1 and R^2 is OH and the other is OR^7.

5. The compound according to claim 1 wherein each of R^1 and R^2 is OR^7.

6. The compound according to any one of claims 1 4, or 5 wherein R^7 is an optionally substituted C_{1-6} alkyl.

7. The compound according to claim 6 wherein R^7 methyl.

8. The compound according to claim 6 wherein R^7 is C_{1-4} alkyl substituted with $NR^{22}R^{23}$ wherein each of R^{22} and R^{23} is independently selected from H or a C_{1-3} alkyl.

9. The compound according to claim 8 where R^7 is $-(CH_2)_3NH_2$.

10. . The compound according to any one of claims 1 to 9, wherein R^3 is selected from the group consisting of optionally substituted C_{3-6} alkyl, optionally substituted C_{3-6} alkenyl, optionally substituted C_{3-6} alkynyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted C_{3-6} cycloalkyl and optionally substituted C_{3-6} cycloalkenyl.

11. The compound according to claim 10 wherein R^3 is selected from the group consisting of optionally substituted C_{3-6} alkyl and optionally substituted C_{3-6} cycloalkyl.

12. The compound according to any one of claims 1 to 11 wherein R^3 is selected from optionally substituted isopropyl, optionally substituted n-propyl, optionally substituted n-butyl, optionally substituted t-butyl, optionally substituted sec-butyl, optionally substituted n-pentyl, optionally substituted isopentyl, optionally substituted 2-methyl butyl, and optionally substituted n-hexyl.

13. The compound according to claim 12 wherein R^3 is isopropyl or *t*-butyl.

14. The compound according to claim 12 wherein R^3 is isopropyl.

15. The compound according to any one of claims 1 to 10 wherein R^3 is selected from the group consisting of optionally substituted cyclopropyl, optionally substituted cyclopentyl and optionally substituted cyclohexyl ring.

16. The compound according to claim 15 wherein R^3 is cyclopentyl.

17. The compound according to any one of claims 1 to 16, wherein each of R^4, R^5, and R^6 is H.

18. The compound of claim 1 wherein:

R^1 is selected from the group consisting of OH and OR^7, wherein R^7 is optionally substituted $C_{1\text{-}6}$ alkyl;

R^2 is selected from the group consisting of OH and OR^7, wherein R^7 is optionally substituted $C_{1\text{-}6}$ alkyl;

R^3 is optionally substituted $C_{1\text{-}6}$ alkyl;

R^4 is selected from the group consisting of H, $-(CR^{18}R^{19})_tCOOR^8$, and $-(CR^{18}R^{19})_tC(O)NR^9R^{10}$; wherein t is 0, R^8 is selected from the group consisting of H and optionally substituted $C_{1\text{-}6}$ alkyl, R^9 is H and R^{10} is optionally substituted $C_{1\text{-}6}$ alkyl;

R^5 is H; and

R^6 is selected from the group onsisting of H and halo.

19. The compound according to claim 1 wherein:

R^1 is selected from the group consisting of OH and OR^7, wherein R^7 is $C_{1\text{-}6}$ alkyl;

R^2 is selected from the group consisting of OH and OR^7, wherein R^7 is $C_{1\text{-}6}$ alkyl substituted with $NR^{22}R^{23}$, wherein R^{22} and R^{23} are independently selected from H and $C_{1\text{-}3}$ alkyl;

R^3 is optionally substituted $C_{1\text{-}6}$ alkyl;

R^4 is selected from the group consisting of H, -COOH, $-COOCH_3$, and $-C(O)NR^9R^{10}$; wherein R^9 is H and R^{10} is selected from the group consisting of amino substituted $C_{1\text{-}6}$ alkyl and $–(CH_2)_2NHC(O)O$-*t*-butyl;

R^5 is H; and

R^6 is selected from the group onsisting of H and halo.

20. The compound according to claim 1 wherein:

R^1 is selected from the group consisting of OH and -OCH_3;

R^2 is selected from the group consisting of OH, -OCH_3 and -O-$(CH_2)_3NH_2$;

R^3 is $C_{1\text{-}6}$ alkyl;

R^4 is selected from the group consisting of H, -COOH, -$COOCH_3$, -$C(O)NH(CH_2)_2NH_2$; and -$C(O)NH(CH_2)_2NHC(O)O$-*t*-butyl;

R^5 is H; and

R^6 is selectd from the group consisting of H and bromo.

21 . The compound according to claim 1 wherein:

R^1 is selected from the group consisting of OH and -OCH_3;

R^2 is selected from the group consisting of OH, -$OCH_3$and –O-$(CH_2)_3NH_2$;

R^3 is isopropyl;

R^4 is selected from the group consisting of H, -COOH, -$COOCH_3$, -$C(O)(CH_2)_2NH_2$; and -$C(O)NH(CH_2)_2NHC(O)O$-*t*-butyl;

R^5 is H; and

R^6 is selected from the group consisting of H and bromo.

22. . A compound selected from the group consisting of :



,



,



,



,


,

,

, and

, or a salt, solvate or hydrate thereof.

23. A compound which is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

24. A compound of the formula:


.

25. A pharmaceutical composition comprising a compound according to any one of claims 1 to 24 and a pharmaceutically acceptable carrier or diluent.

26. . A method of treating or preventing a condition in a mammal associated with AhR imbalance comprising administering to said mammal an effective amount of a compound according to any one of claims 1 to 24 or a composition of claim 25.

27. A method of treating or preventing an inflammatory disorder in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to any one of claims 1 to 24 or a composition of claim 25.

28. The method according to claim 27 wherein the inflammatory disorder is selected from the group consisting of psoriasis, atopic dermatitis, vitiligo, acne,

neovascular (dry) AMD, neovascular (wet) AMD, uveitis or other inflammatory eye conditions, radiation dermatitis, COPD, asthma, multiple sclerosis (MS), and inflammatory bowel disease.

29. The method according to claim 28 wherein the compound, or a pharmaceutically acceptable salt, solvate or hydrate thereof, is administered topically.

30. The method of claim 28 wherein the inflammatory disorder is psoriasis or atopic dermatitis.

31. A method of treating or preventing psoriasis or atopic dermatitis in a subject in need thereof, comprising administering to the subject an effective amount of 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

32. A compound of Formula (II)



(II)

wherein

each R^1 and R^2 is independently selected from the group consisting of OH, OR^7, and H, provided that at least one of R^1 and R^2 is OH or OR^7;

R^7 is independently selected from the group consisting of optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, and acyl;

R^3 is selected from optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted C_{4-6} cycloalkenyl, halo, cyano, $-C(O)OR^8$, $-NR^9R^{10}$, $-S(O)_2NR^9R^{10}$, $-C(O)R^{11}$, $-OR^{12}$, $-S(O)_nR^{13}$ and optionally substituted heterocyclic ring;

n is an integer having a value of 0, 1 or 2;

R^6 is H;

R^8 is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl;

each of R^9 and R^{10} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl; alternatively, R^9 and R^{10} together with the nitrogen atom to which they are attached, form a 5-7 membered cyclic saturated or unsaturated ring;

R^{11} is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl;-NR^9R^{10}, and -OR^{12};

each of R^{12} and R^{13} is independently is selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl; and

R^6 is selected from the group consisting of halo, hydroxyl, alkoxy, optionally substituted C_{1-6} alkyl, halogenated alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, and optionally substituted aryl C_{1-6} alkyl.

33. Some embodiments describe a process for preparing a compound of Formula 8



8

or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising:

a) preparing a compound of Formula 5



5

or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising

1) alkylating 2,6-dihydroxyacetophenone or a pharmaceutically acceptable salt, solvate or hydrate thereof, to form a compound of Formula 2



2

or a pharmaceutically acceptable salt, solvate or hydrate thereof;

2) treating the ketone of Formula 2 or a pharmaceutically acceptable salt, solvate or hydrate thereof with a Grignard reagent, followed by elimination of water under acidic conditions to form a compound of Formula 3



3

or a pharmaceutically acceptable salt, solvate or hydrate thereof;

3) hydrogenating the compound of Formula 3 or a pharmaceutically acceptable salt, solvate or hydrate thereof to form a compound of Formula 4



4

or a pharmaceutically acceptable salt, solvate or hydrate thereof; and

4) borylating the compound of Formula 4 or a pharmaceutically acceptable salt, solvate or hydrate thereof to form the compound of Formula 5

or a pharmaceutically acceptable salt, solvate or hydrate thereof;

b) preparing a compound of Formula 6



6

or a pharmaceutically acceptable salt, solvate or hydrate thereof comprising treating isoquinoline-3-ol with a triflating agent; and

c) coupling the compound of Formula 6 or a pharmaceutically acceptable salt, solvate or hydrate thereof with the compound of Formula 5 or a pharmaceutically acceptable salt, solvate or hydrate thereof to form a compound of Formula 7



7

or a pharmaceutically acceptable salt, solvate or hydrate thereof; and

d) demethylating the compound of Formula 7 to form the compound of Formula 8.

or a pharmaceutically acceptable salt, solvate or hydrate thereof; wherein steps a and b can be done in either order or simultaneously in different reaction vessels.

34. The process according to claim 33, further comprising purifying the compound of Formula 8.

35. The process according to claim 34 wherein the purifying comprises crystallization.

What is claimed is:

1. A compound of Formula (I), or a salt, solvate or hydrate thereof



(I)

wherein

each of R^1 and R^2 is independently selected from the group consisting of OH, OR^7, and H, provided that at least one of R^1 and R^2 is -OH or -OR^7;

R^7 is selected from the group consisting of optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, aryl C_{1-6} alkyl and acyl;

R^3 is selected from the group consisting of optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted C_{4-6} cycloalkenyl, halo, cyano, -$C(O)OR^8$, -NR^9R^{10}, -$S(O)_2NR^9R^{10}$, -$C(O)R^{11}$, -OR^{12}, -$S(O)_n$ R^{13}, and optionally substituted heterocyclyl;

R^8 is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl;

each of R^9 and R^{10} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, or alternatively, R^9 and R^{10} together with the nitrogen atom to which they are attached form a 5-7 membered cyclic saturated or unsaturated ring;

R^{11} is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, -NR^9R^{10}, and -OR^{12};

each of R^{12} and R^{13} is independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl;

R^6 is selected from the group consisting of H, halo, hydroxyl, alkoxy, optionally substituted C_{1-6} alkyl, halogenated alkyl; optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, and optionally substituted aryl C_{1-6} alkyl;

n is an integer having a value of 0, 1 or 2;

s is an integer having a value of 0, 1 or 2;

t is an integer having a value of 0 to 6;

R^5 is selected from the group consisting of H, halo, optionally substituted C_{1-6} alkyl, $-C(O)OR^{14}$, $-C(O)NR^{15}R^{16}$, aryl and $-C_{1-6}$ alkylaryl;

R^{14} is selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl;

each of R^{15} and R^{16} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, and optionally substituted C_{3-6} cycloalkyl; alternatively R^{15} and R^{16} together with the nitrogen to which they are attached, form a 5-7 membered cyclic saturated or unsaturated ring;

R^4 is selected from the group consisting of H, halo, cyano, optionally substituted C_{1-6} alkyl, optionally substituted C_{2-6} alkenyl, optionally substituted C_{2-6} alkynyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, $-(CR^{18}R^{19})_tCOOR^8$, $-(CR^{18}R^{19})_tOC(O)R^8$, $-(CR^{18}R^{19})_tNR^9R^{10}$, $-(CR^{18}R^{19})_tC(O)NR^9R^{10}$, $-(CR^{18}R^{19})_tNR^9C(O)R^8$, $-(CR^{18}R^{19})_tS(O)_2NR^9R^{10}$, $-(CR^{18}R^{19})_tCOR^{11}$, $-(CR^{18}R^{19})_tCH(O)$, $-(CR^{18}R^{19})_tOR^{12}$, $-(CR^{18}R^{19})_tS(O)_sR^{13}$, optionally substituted heterocyclic, and optionally substituted heterocyclic C_{1-6} alkyl; and

each of R^{18} and R^{19} is independently selected from the group consisting of H, optionally substituted C_{1-6} alkyl, optionally substituted C_{3-6} cycloalkyl, optionally substituted aryl, and optionally substituted aryl C_{1-6} alkyl.

2. A compound selected from the group consisting of:



,


,



,


,



,


,



, and


, or a salt, solvate or hydrate thereof.

3. A compound which is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol, or a pharmaceutically acceptable salt, solvate or hydrate thereof.

4. A compound of the formula:



;

or a salt, solvate or hydrate thereof.

5. The compound of claim 4 that is



.

6. A compound of claim 4 that is at least 90% pure by weight.

7. A compound of claim 4 that is at least 95% pure by weight.

8. A compound of claim 4 that is at least 98% pure by weight.

9. A compound of claim 4 that is s at least 99% pure by weight.

10. A pharmaceutical composition comprising a compound according to claim 1 or 2 and a pharmaceutically acceptable carrier or diluent.

11. A pharmaceutical composition comprising a compound according to any one of claim 3 to 9 and a pharmaceutically acceptable carrier or diluent.

12. The pharmaceutical composition of claim 11, wherein the carrier or diluent is suitable for oral, topical, parenteral, transdermal, intranasal or oral inhalation administration.

13. Use of the compound according to claim 1 or 2 or the pharmaceutical composition according to any one of claims 10 to 12 in the manufacture of a medicament for treating or preventing a condition in a mammal associated with AhR imbalance, wherein an effective amount of the compound or the pharmaceutical composition is to be administered to said mammal.

14. Use of the compound according to claim 1 or 2 or the pharmaceutical composition according to any one of claims 10 to 12 in the manufacture of a medicament for treating or preventing an inflammatory disorder in a subject, wherein an effective amount is to be administered to said subject in need thereof.

15. The use according to claim 14 wherein the inflammatory disorder is selected from the group consisting of psoriasis, atopic dermatitis, vitiligo, acne, neovascular (dry) AMD, neovascular (wet) AMD, uveitis or other inflammatory eye conditions, radiation dermatitis, COPD, asthma, multiple sclerosis (MS), and inflammatory bowel disease.

16. Use of the compound or the pharmaceutically acceptable, salt, solvate or hydrate thereof, according to any one of claims 3 to 9 in the manufacture of a medicament for treating or preventing an inflammatory disorder in a subject, wherein an effective amount of the compound or the pharmaceutically acceptable, salt, solvate or hydrate thereof is to be administered to said subject in need thereof.

17. The use according to claim 16 wherein the inflammatory disorder is selected from the group consisting of psoriasis, atopic dermatitis, vitiligo, acne, neovascular (dry) AMD, neovascular (wet) AMD, uveitis or other inflammatory eye conditions, radiation dermatitis, COPD, asthma, multiple sclerosis (MS), and inflammatory bowel disease.

18. The use according to claim 16 wherein the inflammatory disorder is selected from the group consisting of psoriasis, atopic dermatitis, vitiligo, acne, uveitis, radiation dermatitis, COPD, asthma, multiple sclerosis (MS), and inflammatory bowel disease.

19. Use of the compound or the pharmaceutically acceptable, salt, solvate or hydrate thereof, according to any one of claims 3 to 9 in the manufacture of a medicament for treating or preventing psoriasis or atopic dermatitis in a subject, wherein an effective amount of the compound or the pharmaceutically acceptable, salt, solvate or hydrate thereof is to be administered to the subject in need thereof.

20. The use according to claim 16 wherein the compound or the pharmaceutically acceptable salt, solvate or hydrate thereof, is to be administered orally, topically, parenterally, transdermally, intranasally, or by oral inhalation.

21. A process for preparing a compound of Formula 8



8

or a pharmaceutically acceptable salt, solvate or hydrate thereof,

comprising:

a) coupling a compound of Formula 6



6,

or a pharmaceutically acceptable salt thereof with a compound of Formula 5



5

or a pharmaceutically acceptable salt thereof to form a compound of Formula 7



7

or a pharmaceutically acceptable salt thereof; and

b) demethylating the compound of Formula 7 to form the compound of Formula 8, and optionally converting the compound of Formula 8 to a pharmaceutically acceptable salt, solvate or hydrate thereof.

22. The process of claim 21 wherein the compound of Formula 6 or a pharmaceutically acceptable salt thereof, is prepared by treating isoquinoline-3-ol with a triflating agent.

23. The process of claim 21 wherein the compound of Formula 5 or a pharmaceutically acceptable salt thereof, is prepared by a process comprising:

a) alkylating 2,6-dihydroxyacetophenone or a pharmaceutically acceptable salt, thereof, to form a compound of Formula 2



2

or a pharmaceutically acceptable salt thereof;

b) treating the compound of Formula 2 or a pharmaceutically acceptable salt thereof with a Grignard reagent, followed by elimination of water under acidic conditions to form a compound of Formula 3



3

or a pharmaceutically acceptable salt thereof;

c) hydrogenating the compound of Formula 3 or a pharmaceutically acceptable salt thereof to form a compound of Formula 4



4

or a pharmaceutically acceptable salt thereof; and

d) borylating the compound of Formula 4 or a pharmaceutically acceptable salt thereof to form the compound of Formula 5 or a pharmaceutically acceptable salt thereof.

24. The process of claim 21 wherein the demethylation comprises

a) treating the compound of Formula 7 with boron tribromide to form the compound of Formula 7-1



7-1

and

b) hydrogenating the compound of Formula 7-1 to form the compound of Formula 8.

25. The process of claim 21, further comprising purifying the compound of Formula 8.

26. The process of claim 25 wherein the purifying comprises crystallization

27. A process for preparing a compound of Formula 8



8

or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising:

a) preparing a compound of Formula 5



5

or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising

1) alkylating 2,6-dihydroxyacetophenone or a pharmaceutically acceptable salt, solvate or hydrate thereof, to form a compound of Formula 2



2

or a pharmaceutically acceptable salt, solvate or hydrate thereof;

2) treating the ketone of Formula 2 or a pharmaceutically acceptable salt, solvate or hydrate thereof with a Grignard reagent, followed by elimination of water under acidic conditions to form a compound of Formula 3



3

or a pharmaceutically acceptable salt, solvate or hydrate thereof;

3) hydrogenating the compound of Formula 3 or a pharmaceutically acceptable salt, solvate or hydrate thereof to form a compound of Formula 4



4

or a pharmaceutically acceptable salt, solvate or hydrate thereof; and

4) borylating the compound of Formula 4 or a pharmaceutically acceptable salt, solvate or hydrate thereof to form the compound of Formula 5

or a pharmaceutically acceptable salt, solvate or hydrate thereof;

b) preparing a compound of Formula 6



6

or a pharmaceutically acceptable salt, solvate or hydrate thereof comprising treating isoquinoline-3-ol with a triflating agent; and

c) coupling the compound of Formula 6 or a pharmaceutically acceptable salt, solvate or hydrate thereof with the compound of Formula 5 or a pharmaceutically acceptable salt, solvate or hydrate thereof to form a compound of Formula 7



7

or a pharmaceutically acceptable salt, solvate or hydrate thereof; and

d) demethylating the compound of Formula 7 to form the compound of Formula 8.

or a pharmaceutically acceptable salt, solvate or hydrate thereof; wherein steps a and b can be done in either order or simultaneously in different reaction vessels.

28. The process according to claim 27, further comprising purifying the compound of Formula 8.

29. The process according to claim 27 wherein the purifying comprises crystallization.

30. The compound according to any one of claims 1 to 9, or the pharmaceutical composition according to any one of claims 10 to 12, for use as a medicament.